MedTrace Logo

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

NCT00926614 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-02-14

No results posted yet for this study

Summary

The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.

Conditions

  • Hepatitis c

Interventions

DRUG

pioglitazone (Actos)

pioglitazone 30 mg qd for 30 days, then increase to 45 mg

DRUG

atorvastatin (Lipitor)

atorvastatin 40 mg for 30 days then increase to 80 mg daily

Sponsors & Collaborators

  • Brooke Army Medical Center

    lead FED

Principal Investigators

  • Stephen A Harrison, MD · Brooke Army Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-06-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926614 on ClinicalTrials.gov